Related Experiment Videos
Relationship between initial prostate specific antigen level and subsequent prostate cancer detection in a
Jo Ann V Antenor1, Misop Han, Kimberly A Roehl
1Departments of Neurology, Washington University, School of Medicine, St. Louis, Missouri, USA.
The Journal of Urology
|June 18, 2004
Summary
Initial prostate specific antigen (PSA) screening effectively predicts prostate cancer risk and severity. Even lower PSA levels can identify men at higher risk for developing prostate cancer in long-term studies.
Area of Science:
- Urology
- Oncology
- Preventive Medicine
Background:
- Previous research indicates a link between prostate specific antigen (PSA) and prostate cancer detection in non-screened populations.
- The current study investigates the predictive value of initial PSA screening in a prospective, longitudinal setting.
Purpose of the Study:
- To evaluate the relationship between initial screening PSA levels and the risk of subsequent prostate cancer detection.
- To examine the association between initial PSA and the clinicopathological features of detected prostate cancers.
Main Methods:
- A prospective, longitudinal prostate cancer screening study involving 26,111 volunteers from May 1991 to November 2001.
- Participants underwent screening using PSA and digital rectal examination, with follow-up intervals varying based on prior results.
- Statistical analyses, including chi-square and Kruskal-Wallis tests, compared cancer characteristics across different initial PSA strata.
Main Results:
- A strong association was observed between the initial screening PSA level and the subsequent detection of prostate cancer.
- The initial PSA stratum also correlated significantly with the clinicopathological stage and grade of the detected prostate cancers.
Conclusions:
- Initial serum PSA screening is a valuable tool for identifying men at increased risk of developing prostate cancer.
- Even individuals with lower initial PSA levels can be identified as having an elevated risk through longitudinal screening.